50 results about "Susceptible individual" patented technology

Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

A method of preventing and / or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3.

A method of preventing and / or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3.

Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas. It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof.

The invention discloses a molecular marker for detecting susceptibility of ovarian cancer. Nucleotide sequences of the molecular marker are shown in SEQ ID NO.1, and mononucleotide polymorphism, namely T>C is present at 1506th site. A kit for detecting susceptibility of ovarian cancer comprises a pair of specific primers having sequences in SEQ ID NO.2 and SEQ ID NO.3. A method for detecting presence of mononucleotide polymorphism in GADD45A (growth arrest and DNA-damage-inducible protein 45 alpha) gene in a sample in vitro includes: firstly, amplifying the GADD45A gene in the sample by the specific primers to obtain an amplification product; secondly, subjecting the amplification product to sequence determination, and detecting presence of mononucleotide polymorphism, namely 1506T>C, in the amplification product. The method is simple, accurate and fast in detection and high in specificity, and is important to effectively implementing early diagnosis, early treatment and individual prevention and treatment to high risk groups or susceptible individuals and patients with ovarian cancer.

The invention discloses an influenza prediction system for optimizing LSTM (Long Short Term Memory) and LightGBM parameters. The system comprises an LSTM module, a LightGBM module and a prediction module; the LSTM module is configured to calculate a predicted value n of the number of people infected with influenza in an aggregated group by using LSTM based on historical factor data and external factor data; the LightGBM module is configured to calculate the influenza infection probability of each person in the aggregation group by adopting the LightGBM based on health condition data and surrounding environment data, and an infection probability sequence is obtained by ranking from large to small; the prediction module is configured to select the top n individuals with the highest probability of infecting influenza as high-risk population. The system combines the influenza outbreak trend of the aggregated group with the influenza infection probability of each individual in the group, so that the susceptible individuals in the aggregated group can be accurately predicted; meanwhile, the system adjusts parameters of an LSTM model and a LightGBM algorithm so that the accuracy of a prediction result can be further improved.

The subject invention provides novel amino acid sequences (including a consensus sequence) of the Avian Influenza A virus hemagglutinin protein. These newly constructed genes are designed to provide a broader spectrum of activity across the serotype family thus providing a basis for a vaccine that has broad heterologous disease protection. The novel genes have been further improved by the addition of strategic glycosylation sites into the amino acids sequences that they encode. These genes can also, optionally, be codon optimized for plant expression, inserted into the appropriate vector and cloned into plants for expression. Polypeptides produced by recombinant host cells or transgenic plants can also be used as source of antigen for the formulation of vaccines for the control of influenza in susceptible individuals. Additionally, transgenic plant material may also be used as source of antigen for the formulation of vaccines for the control of influenza in susceptible individuals.